Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

Autor: B. Claudius, Thomas A. Wadden, Christine B. Jensen, A. Blackman, Gary D. Foster, Emmanuel Mignot, Louis J. Aronne, G Zammit, R Rosenberg
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Adult
Male
Pediatrics
medicine.medical_specialty
Adolescent
Endocrinology
Diabetes and Metabolism
Polysomnography
Medicine (miscellaneous)
030209 endocrinology & metabolism
macromolecular substances
law.invention
03 medical and health sciences
Young Adult
0302 clinical medicine
Randomized controlled trial
Double-Blind Method
law
Weight Loss
medicine
Humans
Hypoglycemic Agents
030212 general & internal medicine
Obesity
Prospective Studies
Prospective cohort study
Glycated Hemoglobin
Sleep Apnea
Obstructive
Nutrition and Dietetics
medicine.diagnostic_test
Liraglutide
business.industry
Sleep apnea
Middle Aged
medicine.disease
United States
respiratory tract diseases
Obstructive sleep apnea
Blood pressure
Treatment Outcome
Physical therapy
Original Article
Female
Anti-Obesity Agents
business
medicine.drug
Zdroj: International Journal of Obesity (2005)
ISSN: 1476-5497
0307-0565
Popis: Background: Obesity is strongly associated with prevalence of obstructive sleep apnea (OSA), and weight loss has been shown to reduce disease severity. Objective: To investigate whether liraglutide 3.0 mg reduces OSA severity compared with placebo using the primary end point of change in apnea–hypopnea index (AHI) after 32 weeks. Liraglutide's weight loss efficacy was also examined. Subjects/Methods: In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15–29.9 events h−1) or severe (AHI ⩾30 events h−1) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or placebo (n=179), both as adjunct to diet (500 kcal day−1 deficit) and exercise. Baseline characteristics were similar between groups (mean age 48.5 years, males 71.9%, AHI 49.2 events h−1, severe OSA 67.1%, body weight 117.6 kg, body mass index 39.1 kg m−2, prediabetes 63.2%, HbA1c 5.7%). Results: After 32 weeks, the mean reduction in AHI was greater with liraglutide than with placebo (−12.2 vs −6.1 events h−1, estimated treatment difference: −6.1 events h−1 (95% confidence interval (CI), −11.0 to −1.2), P=0.0150). Liraglutide produced greater mean percentage weight loss compared with placebo (−5.7% vs −1.6%, estimated treatment difference: −4.2% (95% CI, −5.2 to −3.1%), P
Databáze: OpenAIRE
Externí odkaz: